The company will compete with a device Boston Scientific acquired for $850 million.

Dublin, Oct. 22, 2024 (GLOBE NEWSWIRE) -- The "Pain Management Devices Market, Industry Trends and Global Forecasts to 2035: Distribution by Type of Device, Type of Neurostimulation Device ...

The $110 billion medical devices company now has a digital leader who sits on the executive management board of every ...

Dublin, Dec. 18, 2024 (GLOBE NEWSWIRE) -- The "Pain Management Devices Market - A Global and Regional Analysis: Focus on Type, Application, End User, and Country - Analysis and Forecast ...

and pain management. Boston Scientific is renowned for its cutting-edge technologies, such as stents, pacemakers, and endoscopic tools, which enhance patient care and improve clinical outcomes.

Boston Scientific has proven ... in spinal cord stimulation for chronic pain. The 2020 dip in profitability due to covid notwithstanding, management's efforts to streamline operations and enhance ...

Boston Scientific ... rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment ...

Boston Scientific Corporation ... BSX is under-leveraged in pain treatment, and I think this is an area that could use some extra management attention to rectify. Lastly, I do have some concerns ...

dividend-frequency { font-size: 12px; color: #6c757d; } Upon a comprehensive analysis of Boston Scientific, the following trends can be discerned: At 63.96, the stock's Price to Earnings ratio ...